HC Wainwright Forecasts Strong Price Appreciation for Karyopharm Therapeutics (NASDAQ:KPTI) Stock

Karyopharm Therapeutics (NASDAQ:KPTI) had its price target lifted by research analysts at HC Wainwright from $7.00 to $56.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q1 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.10) EPS, FY2026 earnings at ($0.87) EPS and FY2027 earnings at ($0.46) EPS.

A number of other equities analysts have also recently issued reports on KPTI. StockNews.com cut shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. Piper Sandler increased their price objective on shares of Karyopharm Therapeutics from $60.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $45.00 price objective on shares of Karyopharm Therapeutics in a research report on Thursday, February 20th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $62.75.

Karyopharm Therapeutics Trading Down 15.1 %

Shares of KPTI opened at $8.35 on Wednesday. The stock has a market capitalization of $70.31 million, a P/E ratio of -8.19 and a beta of 0.06. The firm’s fifty day simple moving average is $9.85 and its two-hundred day simple moving average is $11.28. Karyopharm Therapeutics has a 12 month low of $7.61 and a 12 month high of $25.50.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Wednesday, February 19th. The company reported ($3.60) EPS for the quarter, beating analysts’ consensus estimates of ($3.90) by $0.30. The firm had revenue of $30.54 million for the quarter, compared to the consensus estimate of $30.29 million. As a group, research analysts predict that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.

Institutional Investors Weigh In On Karyopharm Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Velan Capital Investment Management LP acquired a new stake in shares of Karyopharm Therapeutics in the 4th quarter worth about $27,000. Focus Partners Wealth acquired a new stake in shares of Karyopharm Therapeutics in the 4th quarter worth about $31,000. TD Waterhouse Canada Inc. acquired a new stake in shares of Karyopharm Therapeutics in the 4th quarter worth about $32,000. Two Sigma Advisers LP raised its holdings in shares of Karyopharm Therapeutics by 145.5% in the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock worth $52,000 after acquiring an additional 45,400 shares during the last quarter. Finally, Opti Capital Management LP acquired a new stake in shares of Karyopharm Therapeutics in the 4th quarter worth about $85,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).